Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Offi
On June 30, 2025, Madryn Asset Management, LP (Trades, Portfolio) executed a strategic transaction involving the reduction of its holdings in Venus Concept Inc.
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company's ongoing commitment to clinical innovation and excellence
MALVERN.
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives
New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sh
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is enteri
MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM) (the ”Company” or ”Neuronetics”) a vertically integrated, commercial stage,
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM), a commercial stage medical technology company focused on designing, developing, an
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM) (the ”Company”) today announced that it has priced its previously announced unde
MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM) (the ”Company”) today announced that it has commenced an underwritten public off
Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9